CN1109543C
(zh)
*
|
1996-10-11 |
2003-05-28 |
斯卡里斯塔有限公司 |
包括二十碳五烯酸和/或十八碳四烯酸的药物制剂
|
DE69833971T2
(de)
*
|
1998-01-28 |
2006-11-02 |
Warner-Lambert Co. Llc |
Verfahren zur behandlung der alzheimerschen krankheit
|
US6107334A
(en)
|
1998-02-23 |
2000-08-22 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
US7138431B1
(en)
|
1998-02-23 |
2006-11-21 |
Wake Forest University |
Dietary control of arachidonic acid metabolism
|
FR2788437B1
(fr)
*
|
1999-01-14 |
2006-08-11 |
Inst Rech Biolog Sa |
Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
|
AU2006201772B2
(en)
*
|
1999-01-27 |
2010-02-04 |
Amarin Neuroscience Limited |
Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
|
GB9901808D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Drugs for treatment of psychiatric and brain disorders
|
GB9901809D0
(en)
*
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
GB9904895D0
(en)
*
|
1999-03-03 |
1999-04-28 |
Scarista Limited |
Regulators of coenzyme-A-independent transacylase as psychotropic drugs
|
US8030294B2
(en)
*
|
2000-03-16 |
2011-10-04 |
The Mclean Hospital Corporation |
Compounds for the treatment of psychiatric or substance abuse disorders
|
IL142535A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Pharmaceutical compositions for the treatment of inflammation
|
IL142536A0
(en)
*
|
2001-04-11 |
2002-03-10 |
Yeda Res & Dev |
Carriers for therapeutic preparations for treatment of t-cell mediated diseases
|
WO2002092779A2
(en)
*
|
2001-05-17 |
2002-11-21 |
Pilot Therapeutics, Inc. |
Method for enriching tissues in long chain polyunsaturated fatty acids
|
ATE367172T1
(de)
|
2001-11-08 |
2007-08-15 |
Atrium Medical Corp |
Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
|
NL1019368C2
(nl)
|
2001-11-14 |
2003-05-20 |
Nutricia Nv |
Preparaat voor het verbeteren van receptorwerking.
|
KR20050071565A
(ko)
*
|
2002-10-10 |
2005-07-07 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
지방 알콜의 염기성 에스테르 및 이들의 항염증제 또는면역조절제로서의 용도
|
GB0311081D0
(en)
|
2003-05-14 |
2003-06-18 |
Btg Internat Limted |
Treatment of neurodegenerative conditions
|
US7964641B2
(en)
*
|
2003-08-18 |
2011-06-21 |
Btg International Limited |
Treatment of neurodegenerative conditions
|
AU2004317087A1
(en)
*
|
2003-10-08 |
2005-09-22 |
The Mclean Hospital Corporation |
Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
|
US20050113449A1
(en)
*
|
2003-10-08 |
2005-05-26 |
Renshaw Perry F. |
Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
|
US20090215896A1
(en)
*
|
2004-01-19 |
2009-08-27 |
Martek Biosciences Corporation |
Reelin deficiency or dysfunction and methods related thereto
|
ITMI20040069A1
(it)
*
|
2004-01-21 |
2004-04-21 |
Tiberio Bruzzese |
Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
|
US7022713B2
(en)
*
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
US20050266051A1
(en)
*
|
2004-05-27 |
2005-12-01 |
The Procter & Gamble Company |
Pet food compositions and methods
|
WO2005123097A1
(en)
*
|
2004-06-10 |
2005-12-29 |
Mclean Hospital Corporation |
Pyrimidines, such as cytidine, in treatments for patients with bipolar disorder
|
US7737128B2
(en)
*
|
2004-06-10 |
2010-06-15 |
The Mclean Hospital Corporation |
Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
|
WO2006020703A1
(en)
*
|
2004-08-11 |
2006-02-23 |
The Mclean Hospital Corporation |
Compounds for the treatment of marihuana dependence, withdrawal, and usage
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
US8124127B2
(en)
|
2005-10-15 |
2012-02-28 |
Atrium Medical Corporation |
Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
|
US20090011116A1
(en)
*
|
2004-09-28 |
2009-01-08 |
Atrium Medical Corporation |
Reducing template with coating receptacle containing a medical device to be coated
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
EP1804717A4
(de)
|
2004-09-28 |
2015-11-18 |
Atrium Medical Corp |
Arzneiabgabebeschichtung zur verwendung mit einem stent
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US9801913B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Barrier layer
|
US20060083768A1
(en)
*
|
2004-09-28 |
2006-04-20 |
Atrium Medical Corporation |
Method of thickening a coating using a drug
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US7550286B2
(en)
*
|
2004-11-04 |
2009-06-23 |
E. I. Du Pont De Nemours And Company |
Docosahexaenoic acid producing strains of Yarrowia lipolytica
|
US7893106B2
(en)
*
|
2004-11-19 |
2011-02-22 |
Martek Biosciences, Corporation |
Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
|
BRPI0516803A
(pt)
*
|
2004-11-19 |
2008-09-23 |
Martek Biosciences Corp |
oxilipinas de ácidos graxos polinsaturados de cadeia longa e métodos de produção e uso dos mesmos
|
US20090318394A1
(en)
*
|
2004-11-19 |
2009-12-24 |
Julie Nauroth |
Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
|
GB0425932D0
(en)
*
|
2004-11-25 |
2004-12-29 |
Btg Int Ltd |
Structured phospholipids
|
GB2421909A
(en)
*
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
GB0504362D0
(en)
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Cytokine modulators
|
GB0504333D0
(en)
*
|
2005-03-02 |
2005-04-06 |
Btg Int Ltd |
Treatment of cytokine dysregulation
|
KR20130101596A
(ko)
*
|
2005-07-08 |
2013-09-13 |
마텍 바이오싸이언스스 코포레이션 |
치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
ES2511772T3
(es)
*
|
2005-12-20 |
2014-10-23 |
Cenestra, Llc |
Formulaciones de ácidos grasos omega-3
|
EP1983977A4
(de)
*
|
2006-01-31 |
2011-11-30 |
Martek Biosciences Corp |
Oxylipine aus stearidonsäure und gamma-linolensäure sowie verfahren zu ihrer herstellung und verwendung
|
EP2626091B1
(de)
|
2006-11-06 |
2016-09-28 |
Atrium Medical Corporation |
Beschichtetes chirurgisches Netz
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
US20100130611A1
(en)
*
|
2006-12-20 |
2010-05-27 |
Cenestra Llc |
Omega 3 fatty acid formulations
|
WO2008103753A2
(en)
*
|
2007-02-20 |
2008-08-28 |
Martek Biosciences Corporation |
Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
|
EP2117301A4
(de)
*
|
2007-02-26 |
2010-04-14 |
Yeda Res & Dev |
Verwendung langkettiger alkoholderivate zur behandlung von kreisrundem haarausfall
|
WO2008106092A1
(en)
*
|
2007-02-26 |
2008-09-04 |
Yeda Research And Development Co. Ltd. |
Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
|
US8323935B2
(en)
*
|
2007-10-03 |
2012-12-04 |
E I Du Pont De Nemours And Company |
Optimized strains of Yarrowia lipolytica for high eicosapentaenoic acid production
|
CA2704371A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Wake Forest University School Of Medicine |
Compositions and methods for prevention and treatment of mammalian diseases
|
US8343753B2
(en)
*
|
2007-11-01 |
2013-01-01 |
Wake Forest University School Of Medicine |
Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
|
WO2009086281A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Martek Biosciences Corporation |
Method for preparation of oxylipins
|
US20100041621A1
(en)
*
|
2008-08-15 |
2010-02-18 |
Perry Renshaw |
Methods and compositions for improving cognitive performance
|
JP5924834B2
(ja)
|
2008-09-02 |
2016-05-25 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
エイコサペンタエン酸およびニコチン酸を含む製薬組成物ならびにこの製薬組成物を用いる方法
|
AU2015203289B2
(en)
*
|
2008-09-09 |
2017-03-16 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
AU2008361645A1
(en)
|
2008-09-09 |
2010-03-18 |
Orygen Research Centre |
Prevention of psychotic disorders and/or treatment of psychotic symptoms
|
US8060617B2
(en)
*
|
2008-12-19 |
2011-11-15 |
Cisco Technology, Inc. |
Reserving network resources during scheduling of meeting event
|
LT3037089T
(lt)
|
2009-02-10 |
2020-01-10 |
Amarin Pharmaceuticals Ireland Limited |
Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
|
GB0904300D0
(en)
|
2009-03-12 |
2009-04-22 |
Amarin Neuroscience Ltd |
Essential fatty acid compounds
|
US20120100208A1
(en)
|
2009-04-29 |
2012-04-26 |
Amarin Pharma, Inc. |
Stable pharmaceutical composition and methods of using same
|
MY198422A
(en)
|
2009-04-29 |
2023-08-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
KR20120016677A
(ko)
|
2009-06-15 |
2012-02-24 |
아마린 파마, 인크. |
병용 스타틴 요법을 받는 대상체에서 ldl-c 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
NZ599061A
(en)
|
2009-09-23 |
2014-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
US8372465B2
(en)
|
2010-02-17 |
2013-02-12 |
Bunge Oils, Inc. |
Oil compositions of stearidonic acid
|
AU2011222544A1
(en)
*
|
2010-03-04 |
2012-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
EP2593141B1
(de)
|
2010-07-16 |
2018-07-04 |
Atrium Medical Corporation |
Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
NZ611606A
(en)
|
2010-11-29 |
2015-10-30 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
WO2012083034A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Louis Sanfilippo |
Modulation of neurotrophic factors by omega-3 fatty acid formulations
|
US8951514B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
|
US8952000B2
(en)
|
2011-02-16 |
2015-02-10 |
Pivotal Therapeutics Inc. |
Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
|
US8715648B2
(en)
|
2011-02-16 |
2014-05-06 |
Pivotal Therapeutics Inc. |
Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
|
US9119826B2
(en)
|
2011-02-16 |
2015-09-01 |
Pivotal Therapeutics, Inc. |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
|
EP2540292A1
(de)
*
|
2011-06-28 |
2013-01-02 |
Nestec S.A. |
DHA und EPA zur Reduktion oxidativer Belastung
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
AU2013207368A1
(en)
|
2012-01-06 |
2014-07-24 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
MX2015000138A
(es)
|
2012-06-29 |
2015-09-07 |
Amarin Pharmaceuticals Ie Ltd |
Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
CN106102765A
(zh)
|
2014-02-07 |
2016-11-09 |
犹他大学研究基金会 |
肌酸、ω‑3脂肪酸和胞磷胆碱的组合
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2016063959A1
(ja)
*
|
2014-10-24 |
2016-04-28 |
日油株式会社 |
環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
|
ES2607715B1
(es)
*
|
2015-10-01 |
2018-01-17 |
Solutex Na, Lcc |
Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
JP7020756B2
(ja)
|
2018-09-24 |
2022-02-16 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
対象の心血管イベントのリスクを低減する方法
|